{"entity":{"type":"insider","cik":"0001818576","url":"/insider/0001818576","json_url":"/insider/0001818576.json","name":"Rankin Aubrey","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":12,"n_filings":11,"first":"2020-09-30","last":"2021-12-06","span_basis":"filed_date"},"name_variants":[{"name":"Rankin Aubrey","source":"filing","n_filings":11,"first_seen":"2020-09-30","last_seen":"2021-12-06"}],"transactions":[{"id":4096869,"accession":"0001479290-21-000171","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-21-000171","line_url":"/filing/0001479290-21-000171#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001818576","owner_name":"Rankin Aubrey","owner_display_name":"Rankin Aubrey","owner_url":"/insider/0001818576","role":"Director, Officer (President, Innovation & Tech)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Innovation & Tech","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":14.4292,"price_display":"14.43","price_state":"stated","total_value":432876.0,"total_display":"432,876.00","total_whole":"432,876","shares_owned_after":95463.0,"shares_owned_after_display":"95,463","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-03","filed_date":"2021-12-06","scope":"insider"},{"id":4200497,"accession":"0001479290-21-000152","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001479290-21-000152","line_url":"/filing/0001479290-21-000152#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001818576","owner_name":"Rankin Aubrey","owner_display_name":"Rankin Aubrey","owner_url":"/insider/0001818576","role":"Director, Officer (President, Innovation & Tech)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Innovation & Tech","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9364.0,"shares_display":"9,364","price_per_share":26.3412,"price_display":"26.34","price_state":"stated","total_value":246658.9968,"total_display":"246,659.00","total_whole":"246,659","shares_owned_after":65463.0,"shares_owned_after_display":"65,463","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-16","filed_date":"2021-08-17","scope":"insider"},{"id":4695777,"accession":"0001479290-21-000141","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001479290-21-000141","line_url":"/filing/0001479290-21-000141","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001818576","owner_name":"Rankin Aubrey","owner_display_name":"Rankin Aubrey","owner_url":"/insider/0001818576","role":"Director, Officer (President, Innovation & Tech)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Innovation & Tech","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":54332.0,"shares_display":"54,332","price_per_share":30.055216078922182,"price_display":"30.06","price_state":"stated","total_value":1632960.0,"total_display":"1,632,960.00","total_whole":"1,632,960","shares_owned_after":321611.0,"shares_owned_after_display":"321,611","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-28","filed_date":"2021-07-30","scope":"insider","n_lines":2},{"id":5223186,"accession":"0001479290-21-000139","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-21-000139","line_url":"/filing/0001479290-21-000139#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001818576","owner_name":"Rankin Aubrey","owner_display_name":"Rankin Aubrey","owner_url":"/insider/0001818576","role":"Director, Officer (President, Innovation & Tech)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Innovation & Tech","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55382.0,"shares_display":"55,382","price_per_share":29.72,"price_display":"29.72","price_state":"stated","total_value":1645953.04,"total_display":"1,645,953.04","total_whole":"1,645,953","shares_owned_after":355943.0,"shares_owned_after_display":"355,943","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-26","filed_date":"2021-07-28","scope":"insider"},{"id":4158039,"accession":"0001479290-21-000093","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-21-000093","line_url":"/filing/0001479290-21-000093#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001818576","owner_name":"Rankin Aubrey","owner_display_name":"Rankin Aubrey","owner_url":"/insider/0001818576","role":"Director, Officer (President, Innovation & Tech)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Innovation & Tech","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2.0,"shares_display":"2","price_per_share":28.28,"price_display":"28.28","price_state":"stated","total_value":56.56,"total_display":"56.56","total_whole":"57","shares_owned_after":411325.0,"shares_owned_after_display":"411,325","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-05","filed_date":"2021-04-06","scope":"insider"},{"id":5484832,"accession":"0001479290-21-000063","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-21-000063","line_url":"/filing/0001479290-21-000063#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001818576","owner_name":"Rankin Aubrey","owner_display_name":"Rankin Aubrey","owner_url":"/insider/0001818576","role":"Director, Officer (President, Innovation & Tech)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Innovation & Tech","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33119.0,"shares_display":"33,119","price_per_share":25.43,"price_display":"25.43","price_state":"stated","total_value":842216.17,"total_display":"842,216.17","total_whole":"842,216","shares_owned_after":411327.0,"shares_owned_after_display":"411,327","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-03-04","filed_date":"2021-03-05","scope":"insider"},{"id":5223164,"accession":"0001479290-21-000026","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-21-000026","line_url":"/filing/0001479290-21-000026#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001818576","owner_name":"Rankin Aubrey","owner_display_name":"Rankin Aubrey","owner_url":"/insider/0001818576","role":"Director, Officer (President, Innovation & Tech)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Innovation & Tech","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33119.0,"shares_display":"33,119","price_per_share":25.95,"price_display":"25.95","price_state":"stated","total_value":859438.05,"total_display":"859,438.05","total_whole":"859,438","shares_owned_after":444446.0,"shares_owned_after_display":"444,446","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-01","filed_date":"2021-02-03","scope":"insider"},{"id":4990034,"accession":"0001479290-21-000007","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-21-000007","line_url":"/filing/0001479290-21-000007#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001818576","owner_name":"Rankin Aubrey","owner_display_name":"Rankin Aubrey","owner_url":"/insider/0001818576","role":"Director, Officer (President, Innovation & Tech)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Innovation & Tech","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33119.0,"shares_display":"33,119","price_per_share":27.8152,"price_display":"27.82","price_state":"stated","total_value":921211.6088,"total_display":"921,211.61","total_whole":"921,212","shares_owned_after":477565.0,"shares_owned_after_display":"477,565","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-30","filed_date":"2021-01-04","scope":"insider"},{"id":2127237,"accession":"0001479290-20-000110","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-20-000110","line_url":"/filing/0001479290-20-000110#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001818576","owner_name":"Rankin Aubrey","owner_display_name":"Rankin Aubrey","owner_url":"/insider/0001818576","role":"Director, Officer (President, Innovation & Tech)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Innovation & Tech","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33119.0,"shares_display":"33,119","price_per_share":23.85,"price_display":"23.85","price_state":"stated","total_value":789888.15,"total_display":"789,888.15","total_whole":"789,888","shares_owned_after":510684.0,"shares_owned_after_display":"510,684","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-11-30","filed_date":"2020-12-02","scope":"insider"},{"id":2821761,"accession":"0001479290-20-000093","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-20-000093","line_url":"/filing/0001479290-20-000093#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001818576","owner_name":"Rankin Aubrey","owner_display_name":"Rankin Aubrey","owner_url":"/insider/0001818576","role":"Director, Officer (President, Innovation & Tech)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Innovation & Tech","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33119.0,"shares_display":"33,119","price_per_share":26.1466,"price_display":"26.15","price_state":"stated","total_value":865949.2454,"total_display":"865,949.25","total_whole":"865,949","shares_owned_after":543803.0,"shares_owned_after_display":"543,803","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-29","filed_date":"2020-10-30","scope":"insider"},{"id":2273523,"accession":"0001628280-20-014083","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-20-014083","line_url":"/filing/0001628280-20-014083#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001818576","owner_name":"Rankin Aubrey","owner_display_name":"Rankin Aubrey","owner_url":"/insider/0001818576","role":"Director, Officer (President, Innovation & Tech)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Innovation & Tech","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33119.0,"shares_display":"33,119","price_per_share":26.18,"price_display":"26.18","price_state":"stated","total_value":867055.42,"total_display":"867,055.42","total_whole":"867,055","shares_owned_after":576922.0,"shares_owned_after_display":"576,922","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-09-28","filed_date":"2020-09-30","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":12,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":11,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":12},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001479290","name":"Revance Therapeutics, Inc.","url":"/issuer/0001479290","role":"Director, Officer (President, Innovation & Tech)","n_filings":11,"first_seen":"2020-09-30","last_seen":"2021-12-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001818576","retrieved_at":"2026-08-25T21:21:49+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}